OR WAIT null SECS
There are considerations companies may want to consider before seeking out a service provider.
Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.
Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.
November 01, 2023
A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.
October 13, 2023
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.
October 02, 2023
The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.
September 20, 2023
Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance.
CN Bio and LifeNet Health LifeSciences have teamed up to provide direct access to a portfolio of highly characterized hepatic cells for the creation of advanced liver-on-a-chip assays.
September 16, 2023
Plasmid DNA (pDNA) is a critical raw material for the manufacture of cell and gene therapies. As this market continues to grow, so too does the demand for high-quality pDNA.
September 07, 2023
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.
September 01, 2023
The pandemic and shifting focus to more complex therapeutics are driving growth in the outsourced formulation development services market.
August 29, 2023
Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.
August 02, 2023
Broader industry shifts may lead outsourcing companies to prioritize integrated services.